Neuroscience

Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore

Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatmentsHighlighted clinical...

Wonder Sciences Brings 190 Global Leaders to Antarctica for a Landmark Summit on the Future of Mental Healthcare and Advanced AI

A first-of-its-kind scientific expedition examines the next era of precision mental healthcare, psychedelic science and psychedelic-assisted therapy, and AI-driven clinical...

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Paradigm Health Raises $78 Million Series B to Make Clinical Trials Part of Routine Care Across the U.S. and Globally

COLUMBUS, Ohio and NEW YORK, Dec. 4, 2025 /PRNewswire/ -- Paradigm Health, the technology company rebuilding the clinical research ecosystem,...

Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business — To Accelerate U.S. Market

Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.aiTo strengthen revenue growth of...

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...

SoluPet Inc. (SoluPet) Announces Strategic Partnership With CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

Partnership with CHC in Taiwan will pilot SoluPet's flagship Neuronal Defense™ formulation through CHC's veterinary and consumer-health ecosystem TORONTO, ON...

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation...

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...

error: Content is protected !!